Michael Jeltsch is a Professor at the University of Helsinki in the Division of Pharmaceutical Biosciences . He holds affiliations with multiple research entities including the Helsinki Institute of Sustainability Science (HELSUS) , Helsinki One Health (HOH) , and the Drug Research Program . Additionally, he serves as a supervisor for the Doctoral Programme in Drug Research and the Doctoral Programme in Integrative Life Science . Education: Docent in Protein Chemistry, University of Helsinki (2011) Ph.D. in Biochemistry, University of Helsinki (2002) M.Sc. in Biochemistry, University of Helsinki (1997) Vordiplom in Molecular Biology/Biochemistry, University of Hamburg (1992) Baccalaureate, Gymnasium An Der Stenner, Iserlohn (1989) His research spans Biochemistry, Cell and Molecular Biology, Biomedicine, and Pharmacy , with a particular focus on Vascular and Lymphatic System Development . His recent publications highlight investigations into VEGF family dynamics , lymphatic vascular interactions , and novel drug delivery mechanisms for conditions like Parkinson's Disease and Tendinopathy . Articles reveal expertise in growth factor engineering , protease interactions , and regenerative medicine applications . Scientific Awards: Circulation's Best Paper Award 2015 Innoopeli Prize 2022 Mandatum Ph.D. Thesis Prize 2003 Medix Prize of the Minerva Foundation (1998 & 2004) Currently leading the Syöpäsäätiö 2025-26 project, Jeltsch's work addresses cancer research with €19,998.00 in funding. He actively participates in international conferences such as the 23rd International Vascular Biology Meeting (2024) and contributes to public discourse through 20 media engagements on topics like academic freedom and doctoral education reform.




